MarketBeat
22 Aug 2026, 11:02 UTC · 2h ago
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
22 Aug 2026, 11:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Eikon's PARP1-selective inhibitors EIK1003 and EIK1004 demonstrate 650-fold to 800-fold enzymatic selectivity for PARP1 over PARP2. — High selectivity is the primary value driver here, as it potentially reduces hematologic toxicity and allows for higher dosing compared to existing dual inhibitors.
+0.60Early data for EIK1003 combined with paclitaxel in heavily pretreated ovarian and breast cancer patients showed the majority had responses or stable disease. — Positive clinical signals in difficult-to-treat populations provide initial validation of the drug's efficacy and combination potential.
+0.50EIK1005, an oral Werner helicase inhibitor, is currently being evaluated in patients with microsatellite instability with initial data expected at ESMO. — The expansion into a new target (Werner helicase) diversifies the pipeline and represents a potentially new therapeutic class with low myelosuppression.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
EIK1004 is designed to be brain-penetrant to address central nervous system metastases in breast cancer patients. — Addressing CNS metastases targets a significant unmet medical need, expanding the addressable market for the PARP1 program.
+0.30Eikon identified an off-target phosphodiesterase effect for EIK1003 that can increase heart rate, requiring dosing adjustments. — Off-target cardiac effects introduce a potential safety risk that could complicate regulatory approval or limit the therapeutic window.
-0.20Which stocks this story touches
The company presented promising early data on its PARP1 and Werner helicase inhibitor programs, highlighting potential improvements in toxicity and efficacy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
